Reality Check on Chronic Idiopathic Constipation
Market access for chronic idiopathic constipation treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, around 41% of the covered lives in commercial formularies are covered without utilization management restrictions
- Class Trends: In April 2019, Takeda Pharmaceuticals U.S.A., Inc., announced that Motegrity (prucalopride) is commercially available in the U.S. to treat adults with chronic idiopathic constipation
- Key Findings: This class is heavily contracted, with some PBMs excluding Trulance in favor of the older therapies Linzess and Amitiza
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.